Appendix 4E - Preliminary Final Report
Filed with ASX · · 20 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue from ordinary activities, primarily driven by Software-as-a-Service offerings, while other income saw a slight decline. Despite the revenue growth, the company reported a net loss for the period, which reflects ongoing operational challenges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from 4DMedical
- 4DMedical secures $10mstrategic invest' from Pro Medicus
- 4DMedical renews 3 year contract with University of Michigan
- Lung Scan Technology Reveals Hidden Secrets of Airway Disease
- 4DMedical contract with Stanford, includes CTVQ
- Olympus launches new SeleCT Screening campaign
Later from 4DMedical
- FY2025 Full year results
- 4DMedical receives FDA clearance for CTVQ
- 4DMedical receives $6.0m R&D Tax Incentive
- 4DMedical gains U.S. CMS reimbursement for CTVQ
- 4DMedical's CT: VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical